<DOC>
	<DOCNO>NCT02859961</DOCNO>
	<brief_summary>This study Phase 2b/3 , multi-center study design evaluate efficacy , safety , tolerability strategy shift clinically stable patient receive suppressive combination antiretroviral therapy PRO 140 monotherapy maintain viral suppression 48 week follow study entry . Consenting patient shift combination antiretroviral regimen weekly PRO 140 monotherapy 48 week Treatment Phase one week overlap exist retroviral regimen PRO 140 begin study treatment also one week overlap end treatment subject experience virologic failure .</brief_summary>
	<brief_title>Study PRO 140 SC Single Agent Maintenance Therapy Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection</brief_title>
	<detailed_description>The primary objective ass treatment strategy use PRO 140 SC long-acting , single-agent maintenance therapy chronic suppression CCR5-tropic HIV-1 infection . In addition , prognostic factor therapeutic success PRO 140 monotherapy evaluate . The secondary objective trial ass clinical efficacy , safety tolerability parameter follow substitution combination antiretroviral therapy weekly PRO 140 monotherapy .</detailed_description>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<criteria>1 . Males female , age ≥18 year 2 . Receiving combination antiretroviral therapy last 24 week 3 . No change ART within last 4 week prior Screening Visit 4 . Subject two potential alternative approve ART drug option consider . 5 . Exclusive CCR5tropic virus Screening Visit 6 . Plasma HIV1 RNA &lt; 50 copies/mL Screening Visit 7 . CD4 cell count &gt; 200 cells/mm3 since initiation antiretroviral therapy 8 . CD4 cell count &gt; 350 cells/mm3 precede 24 week Screening Visit 9 . Laboratory value Screening : 1 . Absolute neutrophil count ( ANC ) ≥ 750/mm3 2 . Hemoglobin ( Hb ) ≥ 10.5 gm/dL ( male ) ≥ 9.5 gm/dL ( female ) 3 . Platelets ≥ 75,000 /mm3 4 . Serum alanine transaminase ( SGPT/ALT ) &lt; 5 x upper limit normal ( ULN ) 5 . Serum aspartate transaminase ( SGOT/AST ) &lt; 5 x ULN 6 . Bilirubin ( total ) &lt; 2.5 x ULN unless Gilbert 's disease present subject receive atazanavir absence evidence significant liver disease 7 . Creatinine ≤ 1.5 x ULN 10 . Clinically normal rest 12lead ECG Screening Visit , abnormal , consider clinically significant Principal Investigator . 11 . Both male female patient partner childbearing potential must agree use 2 medically accept method contraception course study . 12 . Willing able participate aspect study , include use SC medication , completion subjective evaluation , attendance schedule clinic visit , compliance protocol requirement evidence provide write informed consent . 1 . CXCR4tropic virus dual/mixed tropic ( R5X4 ) virus determine Trofile™ DNA Assay 2 . Hepatitis B infection manifest presence Hepatitis B surface antigen ( HBsAg ) 3 . Any active infection malignancy require acute therapy ( exception local cutaneous Kaposi 's sarcoma ) 4 . Laboratory test value ≥ grade 4 DAIDS laboratory abnormality . 5 . Females pregnant , lactating , breastfeeding , plan become pregnant study 6 . Unexplained fever clinically significant illness within 1 week prior first study dose 7 . Any vaccination within 2 week prior first study dose study . 8 . Subjects fail maraviroc contain regimen . 9 . Subjects weigh &lt; 35kg 10 . History anaphylaxis oral parenteral drug 11 . History Bleeding Disorder patient anticoagulant therapy 12 . Participation experimental drug trial ( ) within 30 day Screening Visit 13 . Any known allergy antibody study drug excipients 14 . Treatment follow : 1 . Radiation cytotoxic chemotherapy 30 day prior screen visit 2 . Immunosuppressants within 60 day prior screen visit 3 . Immunomodulating agent ( e.g. , interleukin , interferon ) , hydroxyurea , foscarnet within 60 day prior screen visit 4 . Oral parenteral corticosteroid within 30 day prior Screening Visit . Subjects chronic steroid therapy &gt; 5 mg/day exclude follow exception : Subjects inhale , nasal , topical steroid exclude 15 . Any clinical condition , Investigator 's judgment , would potentially compromise study compliance ability evaluate safety/efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>